WallStreetZenWallStreetZen

NASDAQ: CORT
Corcept Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CORT

Based on 3 analysts offering 12 month price targets for Corcept Therapeutics Inc

Min Forecast
$121.00+40.53%
Avg Forecast
$135.33+57.17%
Max Forecast
$145.00+68.4%

Should I buy or sell CORT stock?

Based on 3 analysts offering ratings for Corcept Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CORT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CORT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CORT stock forecasts and price targets.

CORT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-25
lockedlocked$00.00+00.00%2025-09-25
lockedlocked$00.00+00.00%2025-08-01

1 of 1

Forecast return on equity

Is CORT forecast to generate an efficient return?

Company
137.93%
Industry
259.27%
Market
228.52%
CORT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CORT forecast to generate an efficient return on assets?

Company
105.82%
Industry
90.14%
CORT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CORT earnings per share forecast

What is CORT's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$1.02+2.2%
Avg 2 year Forecast
$1.35+35.25%
Avg 3 year Forecast
$5.22+422.24%
CORT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CORT revenue forecast

What is CORT's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$835.6M+12.75%
Avg 2 year Forecast
$1.2B+58.94%
Avg 3 year Forecast
$1.6B+117.36%
CORT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CORT earnings growth forecast

How is CORT forecast to perform vs Biotechnology companies and vs the US market?

Company
64.46%
Industry
44.75%
Market
42.88%
CORT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CORT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CORT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CORT revenue growth forecast

How is CORT forecast to perform vs Biotechnology companies and vs the US market?

Company
29.54%
Industry
102.02%
Market
25.67%
CORT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CORT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CORT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CORT$86.11$135.33+57.17%Strong Buy
TECH$61.68$70.33+14.03%Strong Buy
ARWR$61.44$60.71-1.18%Buy
CYTK$65.67$81.64+24.31%Strong Buy
NUVL$109.60$134.29+22.52%Strong Buy
View Top Biotech Stocks

Corcept Therapeutics Stock Forecast FAQ

Is Corcept Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CORT) stock is to Strong Buy CORT stock.

Out of 3 analysts, 2 (66.67%) are recommending CORT as a Strong Buy, 1 (33.33%) are recommending CORT as a Buy, 0 (0%) are recommending CORT as a Hold, 0 (0%) are recommending CORT as a Sell, and 0 (0%) are recommending CORT as a Strong Sell.

If you're new to stock investing, here's how to buy Corcept Therapeutics stock.

What is CORT's earnings growth forecast for 2025-2027?

(NASDAQ: CORT) Corcept Therapeutics's forecast annual earnings growth rate of 64.46% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and it is also forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Corcept Therapeutics's earnings in 2025 is $104,647,000.On average, 7 Wall Street analysts forecast CORT's earnings for 2025 to be $107,502,358, with the lowest CORT earnings forecast at $83,498,407, and the highest CORT earnings forecast at $130,328,201. On average, 7 Wall Street analysts forecast CORT's earnings for 2026 to be $142,267,063, with the lowest CORT earnings forecast at -$76,282,495, and the highest CORT earnings forecast at $313,671,263.

In 2027, CORT is forecast to generate $549,334,944 in earnings, with the lowest earnings forecast at $332,962,782 and the highest earnings forecast at $696,924,532.

What is CORT's revenue growth forecast for 2025-2027?

(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 29.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Corcept Therapeutics's revenue in 2025 is $741,172,000.On average, 6 Wall Street analysts forecast CORT's revenue for 2025 to be $87,899,481,654, with the lowest CORT revenue forecast at $83,281,718,928, and the highest CORT revenue forecast at $91,859,818,024. On average, 6 Wall Street analysts forecast CORT's revenue for 2026 to be $123,911,719,626, with the lowest CORT revenue forecast at $104,609,681,807, and the highest CORT revenue forecast at $153,364,420,386.

In 2027, CORT is forecast to generate $169,458,217,587 in revenue, with the lowest revenue forecast at $107,081,604,906 and the highest revenue forecast at $215,741,033,067.

What is CORT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CORT) forecast ROA is 105.82%, which is higher than the forecast US Biotechnology industry average of 90.14%.

What is CORT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CORT price target, the average CORT price target is $135.33, with the highest CORT stock price forecast at $145.00 and the lowest CORT stock price forecast at $121.00.

On average, Wall Street analysts predict that Corcept Therapeutics's share price could reach $135.33 by Nov 25, 2026. The average Corcept Therapeutics stock price prediction forecasts a potential upside of 57.17% from the current CORT share price of $86.11.

What is CORT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CORT) Corcept Therapeutics's current Earnings Per Share (EPS) is $1.00. On average, analysts forecast that CORT's EPS will be $1.02 for 2025, with the lowest EPS forecast at $0.79, and the highest EPS forecast at $1.24. On average, analysts forecast that CORT's EPS will be $1.35 for 2026, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at $2.98. In 2027, CORT's EPS is forecast to hit $5.22 (min: $3.17, max: $6.63).

What is CORT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CORT) forecast ROE is 137.93%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.